Hepatitis/MASH

Parts of a protein used in some HCV vaccine candidates are far too flexible to be successful.

Tennessee pharmacist admits to falsifying prior authorizations, medical lab reports, and drug test results for at least 51 hepatitis C patients prescribed Sovaldi, Harvoni, Viekira Pak, and Daklinza.

A former Clinical Pharmacy Manager at a Walgreens specialty pharmacy pleaded guilty to health care fraud crimes committed between October 2014 and April 2016.

Researchers examine interventions that may improve adherence in chronic viral hepatitis care.

Top articles of the week from The American Journal of Pharmacy Benefits.

Obstacles exist in making testing and treatment for hepatitis C routine practice in prison.

An update of distribution and circulation of HCV genotypes could help reduce disease burden.

A diagnostic blood test could diagnose patients in early stages of non-alcoholic fatty liver disease.

Coinfection with HIV plus a hepatitis B, C, or both, adds to the risk of non-Hodgkins lymphoma.

Despite widespread criticism, the United States may be paying less for hepatitis c virus drugs than other developed countries.

Six-week direct-acting antiviral treatment regimen with Sovaldi and ribavirin produced sub-optimal results in newly infected hepatitis C patients.

ElastPQ technique can better detect liver fibrosis in patients with hepatitis C.

In case you missed it, here's the hottest news in pharmacy this week:

Study quantifies global body composition changes in patients with hepatitis C.

AbbVie’s experimental drug can treat hepatitis C virus genotypes 1 through 6.

FDA issues boxed warning that hepatitis C direct-acting antivirals may cause hepatitis B to reactivate in coinfected patients.

Experimental hepatitis C medication treats genotypes 1 through 6.

Direct-acting antivirals may cause hepatitis B reactivation in patients with an HCV/HBV co-infection.

Top news of the day from across the health care landscape.

Patients risk the development of thyroid dysfunction from interferon alpha in patients with hepatitis C virus infection.

Ultrasound not deemed to be sufficiently sensitive to detect early stage liver cancer.

An estimated 107,000 veterans are currently undiagnosed or untreated for HCV.

Injection drug users carry a different set of challenges during treatment for hepatitis C virus.

Navigating prior authoization requirements for patients coinfected with hepatitis C and HIV remains a challenge.

Achieving global elimination of the virus starts with illicit drug users accessing curative hepatitis C virus treatments.